⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159571 | 0.60 | — | — | |
| SCHEMBL15279920 | 0.58 | — | — | |
| SCHEMBL9595461 | 0.57 | — | — | |
| SCHEMBL18032691 | 0.57 | GSK3A (0.30) | — | |
| SCHEMBL447698 | 0.57 | — | — | |
| SCHEMBL540499 | 0.56 | — | — | |
| SCHEMBL11629775 | 0.55 | — | — | |
| SCHEMBL3681554 | 0.55 | — | — | |
| SCHEMBL2230333 | 0.54 | — | — | |
| SCHEMBL5323960 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | claimed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | claimed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | claimed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | claimed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | claimed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | claimed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | claimed |
| WO-2009099582-A2 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | claimed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | claimed |
| US-20030162801-A1 | Tricyclic compounds and their uses | GONG BAOQING (US) | 2003-08-28 | — | — | US | claimed |
| JP-2002541258-A | — | — | 2002-12-03 | — | — | JP | claimed |
| WO-2002094824-A1 | PYRIDOPYRIMIDINE COMPOUNDS AND THEIR USES | CELL THERAPEUTICS, INC. (US) | 2002-11-28 | — | — | WO | claimed |
| WO-2002068421-A2 | TRICYCLIC COMPOUNDS AND THEIR ANALOGS AS INHIBITORS OF CYTOKINE SIGNALING | CELL THERAPEUTICS, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| US-20020103211-A1 | TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES | CELL THERAPEUTICS, INC. | 2002-08-01 | — | — | US | claimed |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CELL THERAPEUTICS, INC. | 2002-03-07 | — | — | US | claimed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | claimed |
| US-5185320-A | Antibiotics | GRUPPO LEPETIT S.P.A. (IT) | 1993-02-09 | — | — | US | claimed |
| EP-0391077-A1 | O56-alkyl derivatives of aglycone and pseudoaglycones of teicoplanin | GRUPPO LEPETIT S.p.A. (IT) | 1990-10-10 | — | — | EP | claimed |